ArthroPaint™ is a minimally invasive medical device capable of reconstructing osteochondral lesions directly within the body using 3D bioprinting.
In situ Bioprinting device
1,603
Million USD, Global Cartilage Repair/Regeneration Market by 2025
15.3
CAGR for the 2020-2025 period
5
Annual incidence growth of cartilage procedures
“This device, developed by Cells for Cells thanks to contributions from CORFO and the French-Swiss company MedXCell, has been successfully validated in ex vivo knee and ankle models and is currently being tested in vivo. Once cleared, the ArthroPaint™ would become one of the first in situ bioprinting devices to reach the market.”
Juan Pablo Acevedo, Ph.D.
Director of the Tissue Engineering and Biofabrication R&D Division
Precise reconstruction of osteochondral defects. The ArthroPaint™ is a handheld arthroscopic 3D bioprinting device capable of accurately reconstructing focal defects using a tip that adapts to any lesion in any position on the articular cartilage. Once the lesion is localized, the surgeon can control with high precision the direction of the arthroscopic extension and the aim, speed, and volume of the bioinks’ extrusion. The controlled deposition of bioinks is crucial to ensuring the reproducibility of clinical results, a significant challenge of current surgical strategies and products.
Minimally invasive, minimal time to recovery. Unlike other tools requiring open surgery, the ArthroPaint™ can access the damaged cartilage via a minimally invasive approach. Arthroscopic procedures generally lead to more successful long-term postoperative outcomes, lower patient and healthcare provider costs, and faster recovery. The engineering and medical teams of Cells for Cells recognized this as a differentiating feature that would simplify the adoption of this novel technology.
Bioinks that aim to regenerate hyaline cartilage. The ArthroPaint™ is capable of repairing living tissues using bioinks with regenerative potential. Through this novel in situ bioprinting method, the human body functions as an ‘‘in vivo bioreactor,” governing the development and maturation of the printed construct at the lesion site. It is a pivotal milestone to provide a definite solution toward completely restoring knee and ankle articular cartilage defects.
